From the Society

Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital

Glucometrics database aids tracking, trending


In honor of Diabetes Awareness Month, The Hospitalist spoke recently with Stephanie Dizon, PharmD, BCPS, director of pharmacy at Dignity Health Sequoia Hospital in Redwood City, Calif. Dr. Dizon was the project lead for Dignity Health Sequoia’s participation in the Society of Hospital Medicine’s Glycemic Control eQUIPS program. The Northern California hospital was recognized as a top performer in the program.

Dr. Stephanie Dizon, Dignity Health Sequoia Hospital, Redwood City, Calif.

Dr. Stephanie Dizon

SHM’s eQUIPS offers a virtual library of resources, including a step-by-step implementation guide, that addresses various issues that range from subcutaneous insulin protocols to care coordination and good hypoglycemia management. In addition, the program offers access to a data center for performance tracking and benchmarking.

Dr. Dizon shared her experience as a participant in the program, and explained its impact on glycemic control at Dignity Health Sequoia Hospital.

Could you tell us about your personal involvement with SHM?

I started as the quality lead for glycemic control for Sequoia Hospital in 2017 while serving in the role as the clinical pharmacy manager. Currently, I am the director of pharmacy.

What inspired your institution to enroll in the GC eQUIPS program? What were the challenges it helped you address?

Sequoia Hospital started in this journey to improve overall glycemic control in a collaborative with eight other Dignity Health hospitals in 2011. At Sequoia Hospital, this effort was led by Karen Harrison, RN, MSN, CCRN. At the time, Dignity Health saw variations in insulin management and adverse events, and it inspired this group to review their practices and try to find a better way to standardize them. The hope was that sharing information and making efforts to standardize practices would lead to better glycemic control.

Enrollment in the GC eQUIPS program helped Sequoia Hospital efficiently analyze data that would otherwise be too large to manage. In addition, by tracking and trending these large data sets, it helped us not only to see where the hospital’s greatest challenges are in glycemic control but also observe what the impact is when making changes. We were part of a nine-site study that proved the effectiveness of GC eQUIPS and highlighted the collective success across the health system.

What did you find most useful in the suite of resources included in eQUIPS?

The benchmarking webinars and informational webinars that have been provided by Greg Maynard, MD, over the years have been especially helpful. They have broadened my understanding of glycemic control. The glucometrics database is especially helpful for tracking and trending – we share these reports on a monthly basis with nursing and provider leadership. In addition, being able to benchmark ourselves with other hospitals pushes us to improve and keep an eye on glycemic control.

Are there any other highlights from your participation– and your institution’s – in the program that you feel would be beneficial to others who may be considering enrollment?

Having access to the tools available in the GC eQUIPS program is very powerful for data analysis and benchmarking. As a result, it allows the people at an institution to focus on the day-to-day tasks, clinical initiatives, and building a culture that can make a program successful instead of focusing on data collection.

For more information on SHM’s Glycemic Control resources or to enroll in eQUIPS, visit

Recommended Reading

FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
The Hospitalist
New biomarker model outmatches conventional risk factors for predicting mortality
The Hospitalist
Dapagliflozin meets primary endpoint in the DAPA-HF trial
The Hospitalist
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD
The Hospitalist
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
The Hospitalist
Machine learning–derived risk score predicts heart failure risk in diabetes patients
The Hospitalist
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
The Hospitalist
Certain diabetes drugs may thwart dementia
The Hospitalist
Dapagliflozin approved for reducing HF hospitalization in diabetes
The Hospitalist
New model for CKD risk draws on clinical, demographic factors
The Hospitalist
   Comments ()